CDISC Selects Nextrials as a Registered Solutions Provider
Nextrials, Inc. has been approved by the Clinical Data Interchange Standards Consortium (CDISC) as one of 15 registered solutions providers, and is the only company offering an electronic data capture (EDC) product supporting the CDISC Healthcare Link Initiative. Begun in 2005, the CDISC Healthcare Link Initiative focuses on the interoperability of electronic health records (EHR) platforms with EDC technology for clinical trials.
Nextrials’ Prism™, an EDC and clinical trial management platform, supports CDISC standards. The platform also has been used in a multi-site study where live patient data was collected and shared by what had previously been two disparate data management platforms.
“By using a standards-based process, workflow for clinical research can be integrated into the workflow for clinical care. This streamlines the process for sharing clinical care information for multiple uses including research and public health. It promotes a reduction in time for data entry and increased data accuracy by eliminating transcription," commented Rebecca Kush, CDISC president and CEO.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
